Thrombocytosis and recurrent hepatic outflow obstruction (Budd-Chiari syndrome) after successful thrombolysis: Case report and literature review

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 4, 2002, Pages 369-374

  Randi, Maria Luigia ^a,c   Sartori, Maria Teresa ^a   Luzzatto, Guido ^a   Ruzzon, Elisabetta ^a   Boccagni, Patrizia ^b   Ragazzi, Roberto ^a   Girolami, Antonio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c Department of Medical and Surgical Sciences   (Italy)

Author keywords

Budd Chiari syndrome; Essential thrombocythemia; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOGEN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BUDD CHIARI SYNDROME; CASE REPORT; CAVA VEIN; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HEPATIC VEIN; HUMAN; LIVER BLOOD FLOW; LIVER FUNCTION; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS;

EID: 0036818776     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800409     Document Type: Article

References (28)

1. Valla D, Benhamou JP. Obstruction of hepatic veins or suprahepatic inferior vena cava. Dig Dis 1996;14:99.
2. Levy VG, Ruskone A, Baillou C, et al. Polycythemia and the Budd-Chiari syndrome: Study of serum erythropoietin and bone marrow erythroid progenitors. Hepatology 1985;55:858.
3. Muller EW, De Wolf JTM, Haagsma EB. Portal hypertension as presenting features of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas. Scand J Gastroenterol 1993;28:74.
4. Pagliuca A, Mufti GJ, Janossa-Tahernia T, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis. Possible evidence of an occult myeloproliferative state. Q J Med 1990;76:981.
5. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorders and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:569.
6. Warren RL, Schlant RC, Wenger NK, et al. Treatment of Budd-Chiari syndrome with streptokinase (abstract). Gastroenterology 1972;62:200.
7. Cassel GA, Morley JE. Hepatic vein thrombosis treated with streptokinase. South Afr Med J 1974;48:2319.
8. Greenwood LH, Yrizarry JM, Hallett JW, et al. Urokinase treatment of Budd-Chiari syndrome. AJR 1983;141:1057.
9. Mc Kee CM, Mayne EE, Crothers JG, et al. Budd-Chiari syndrome treated with acylated streptokinase-plasminogen complex. J R Soc Med 1985;78:768.
10. Sholar PW, Bell WR. Thrombolytic therapy for inferior vena cava thrombosis in paroxymal nocturnal hemoglobinuria. Ann Intern Med 1985;103:539.
11. Ilan Y, Oren R, Shouval D. Postpartum Budd-Chiari syndrome with prolonged hypercoagulability state. Am J Obstet Gynecol 1990;162:1164.
12. Kraus TW, Roheren T, Manner M, et al. Successful treatment of complete inferior vena cava thrombosis after liver transplantation by thrombolytic therapy. Br J Surg 1992;79:568.
13. Frank JW, Kamath PS, Stanson AW. Budd-Chiari syndrome: Early intervention with angioplasty and thrombolytic therapy. Mayo Clin Proc 1994;69:877.
14. Mc Mullin MF, Hillmen P, Jackson J, et al. Tissue plasminogen activator for hepatic vein thrombosis in paroxymal nocturnal haemoglobinuria. J Intern Med 1994;235:85.
15. Griffith JF, Mahamoud AEA, Cooper S, et al. Radiological intervention in Budd-Chiari syndrome: Techniques and outcome in 18 patients. Clin Radiol 1996;51:775.
16. Raju GS, Felver M, Olin JW, et al. Thrombolysis for acute Budd-Chiari syndrome: Case report and literature review. Am J Gastroenterol 1996;91:1262.
17. Leebek FWG, Lameris JS, van Buuren HR, et al. Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated with TIPS and thrombolysis. Br J Haematol 1998;102:929.
18. Murphy S, Iland H, Rosenthal D, et al. Essential thrombocythemia: An interim report from the polycythemia vera study group. Semin Hematol 1986;23:177.
19. Dilawari JB, Bambery P, Chawala Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine 1994;73:21.
20. Gray BH, Olin JW, Graor RA, et al. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 1991;99:54.
21. Goldhaber SZ, Kessler CM, Heit JA, et al. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293.
22. Cortellazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556.
23. Cortellazzo S, Finazzi S, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132.
24. Barosi G, Buratti A, Costa A, et al. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 1991;68:2310.
25. Randi ML, Rossi C, Barbone E, et al. Superior sagittal sinus thrombosis in 5 patients with essential thrombocythemia: A possible disease variant. Rev Iberoam Thromb Hemostasia 1994;7:76.
26. Harrison CN, Gale RE, Machin SJ, et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417.
27. Randi ML, Putti MC, Fabris F, et al. Features of essential thrombocythemia in childwood: A study of five children. Br J Haematol 2000;108:86.
28. Luzzatto G, Schaffer AI. The prethrombotic state in cancer. Semin Oncol 1990;17:147.